Onco-Innovations Announces Private Placement
Onco-Innovations (OTCQB:ONNVF) has announced a non-brokered private placement to raise up to $400,000 through the issuance of 243,903 units at $1.64 per unit. Each unit includes one common share and one warrant, with warrants exercisable at $2.05 for 36 months.
The company will issue additional shares as a 1% administrative fee to a third party. Additionally, Onco-Innovations has approved the grant of 119,785 stock options and 960,000 restricted share units (RSUs) under its equity incentive plan. The proceeds will support general corporate purposes and R&D objectives.
Onco-Innovations (OTCQB:ONNVF) ha annunciato un collocamento privato senza intermediari per raccogliere fino a 400.000 $ tramite l'emissione di 243.903 unità al prezzo di 1,64 $ per unità. Ogni unità comprende una azione ordinaria e un warrant, con i warrant esercitabili a 2,05 $ per 36 mesi.
L'azienda emetterà azioni aggiuntive come commissione amministrativa dell'1% a favore di una terza parte. Inoltre, Onco-Innovations ha approvato la concessione di 119.785 opzioni su azioni e 960.000 unità azionarie vincolate (RSU) nell'ambito del suo piano di incentivi azionari. I proventi saranno destinati a scopi aziendali generali e agli obiettivi di ricerca e sviluppo.
Onco-Innovations (OTCQB:ONNVF) ha anunciado una colocación privada sin intermediarios para recaudar hasta 400.000 $ mediante la emisión de 243.903 unidades a 1,64 $ por unidad. Cada unidad incluye una acción común y un warrant, con warrants ejercitables a 2,05 $ durante 36 meses.
La compañía emitirá acciones adicionales como una comisión administrativa del 1% a un tercero. Además, Onco-Innovations ha aprobado la concesión de 119.785 opciones sobre acciones y 960.000 unidades restringidas de acciones (RSU) bajo su plan de incentivos accionarios. Los fondos recaudados apoyarán propósitos corporativos generales y objetivos de I+D.
Onco-Innovations (OTCQB:ONNVF)는 중개인 없이 최대 400,000달러를 조달하기 위해 단위당 1.64달러에 243,903단위를 발행하는 사모 유상증자를 발표했습니다. 각 단위는 보통주 1주와 워런트 1주를 포함하며, 워런트는 36개월 동안 2.05달러에 행사할 수 있습니다.
회사는 제3자에게 1%의 행정 수수료로 추가 주식을 발행할 예정입니다. 또한 Onco-Innovations는 주식 인센티브 계획에 따라 119,785주 주식매수선택권과 960,000주 제한주식단위(RSU) 부여를 승인했습니다. 조달 자금은 일반 기업 목적 및 연구개발 목표를 지원하는 데 사용됩니다.
Onco-Innovations (OTCQB:ONNVF) a annoncé un placement privé sans intermédiaire visant à lever jusqu'à 400 000 $ par l'émission de 243 903 unités au prix de 1,64 $ par unité. Chaque unité comprend une action ordinaire et un warrant, les warrants étant exerçables à 2,05 $ pendant 36 mois.
La société émettra des actions supplémentaires équivalant à 1 % de frais administratifs à un tiers. De plus, Onco-Innovations a approuvé l'attribution de 119 785 options d'achat d'actions et de 960 000 unités d'actions restreintes (RSU) dans le cadre de son plan d'incitation en actions. Les fonds serviront à financer des objectifs généraux d'entreprise et de recherche et développement.
Onco-Innovations (OTCQB:ONNVF) hat eine nicht vermittelte Privatplatzierung angekündigt, um bis zu 400.000 $ durch die Ausgabe von 243.903 Einheiten zu je 1,64 $ pro Einheit zu beschaffen. Jede Einheit umfasst eine Stammaktie und einen Warrant, wobei die Warrants für 36 Monate zu 2,05 $ ausgeübt werden können.
Das Unternehmen wird zusätzliche Aktien als 1% Verwaltungsgebühr an eine Drittpartei ausgeben. Darüber hinaus hat Onco-Innovations die Gewährung von 119.785 Aktienoptionen und 960.000 Restricted Share Units (RSUs) im Rahmen seines Aktienanreizplans genehmigt. Die Erlöse dienen allgemeinen Unternehmenszwecken und Forschungs- und Entwicklungszielen.
- Proceeds will support R&D objectives and working capital needs
- 36-month warrant exercise period provides long-term potential upside
- Small offering size of only $400,000 may indicate limited investor interest
- Potential dilution from new shares, warrants, options, and RSUs
- Additional dilution from 1% administrative fee shares
VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") of up to 243,903 units of the Company (the "Units") at a price of
The Company also intends to issue Shares equal to
Closing of the Private Placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. The Company intends to use the proceeds of the Private Placement for general corporate and working capital purposes, including in pursuit of the Company's operational and research and development objectives.
The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or available exemptions from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.
The Company also announces that its board of directors has approved the grant of an aggregate of 119,785 incentive stock options (the "Options") and 960,000 restricted share units ("RSUs") pursuant to the Company's equity incentive plan.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated use of funds and closing date thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to complete the Private Placement as contemplated, or at all, that the anticipated proceeds may be lower than expected, the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
What is the price per unit in Onco-Innovations (ONNVF) private placement?
How much money is Onco-Innovations (ONNVF) raising in the private placement?
What are the terms of the warrants in ONNVF's private placement?
How many RSUs and options did Onco-Innovations grant?
What is the holding period for securities issued in ONNVF's private placement?
